Latest Breaking News On - Clinical research division - Page 1 : vimarsana.com

Dr Shadman on the Comparative Efficacy of Currently Available BTK Inhibitors in CLL

Mazyar Shadman, MD, MPH, discusses results from a network meta-analysis on the comparative efficacy of BTK inhibitors in relapsed/refractory CLL.

Advances With Erdafitinib Exemplify the Push For Precision Medicine in Urothelial Cancer

Petros Grivas, MD, PhD, expands on key updates in the second-line management of urothelial cancer.

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of ...

– Results from pivotal Phase 2b ReNeu trialofmirdametinib in patients with NF1-PN to be presented in an oral presentation –

Novel chemoimmunotherapy approach shows promise for B-cell acute lymphoblastic leukemia in phase 1 study at Fred Hutch

BTK Inhibitor Combinations Move to Forefront of CLL Investigations, Conversations

Mazyar Shadman, MD, MPH, details the efficacy of BTK inhibitors in the frontline treatment of CLL as well as safety considerations in the relapsed/refractory setting.

Grivas Spotlights Advances With Immunotherapy-Based Approaches in Urothelial Cancer

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.

Dr Grivas on Frontline Treatment Options in Metastatic RCC

Petros Grivas, MD, PhD, discusses frontline treatment options for patients with metastatic renal cell carcinoma.

FDA Approves Danicopan With C5 Inhibitor Therapy to Treat EVH in Adults With Paroxysmal Nocturnal Hemoglobinuria

Positive phase 3 trial results showed that danicopan was more effective than placebo when treating extravascular hemolysis in paroxysmal nocturnal hemoglobinuria.